Phase II randomized clinical trial of LC
β
Tomohiko Okawa; Midori Kita; Tatsuo Arai; Kouyo Iida; Takushi Dokiya; Yoshihiro
π
Article
π
1989
π
John Wiley and Sons
π
English
β 648 KB
The clinical efficacy of LC9018, a biological response modifier prepared from heat-killed Lactobacillus casei YIT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or 111. The combination therapy with